Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 20/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.78 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.78 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29881077 | 1.00 | NR1H4 (0.78) | NR1H4CYP3A4KCNH2CYP2C9CYP2D6 | |
| SCHEMBL3571819 | 0.95 | NR1H4 (0.77) | NR1H4CYP3A4KCNH2CYP2C9CYP2D6 | |
| SCHEMBL29881693 | 0.88 | NR1H4 (1.00) | NR1H4CYP3A4KCNH2CYP2C9CYP2D6 | |
| SCHEMBL29881159 | 0.88 | NR1H4 (1.00) | NR1H4CYP3A4KCNH2CYP2C9CYP2D6 | |
| SCHEMBL29881170 | 0.88 | NR1H4 (1.00) | NR1H4CYP3A4KCNH2CYP2C9CYP2D6 | |
| SCHEMBL29880706 | 0.88 | NR1H4 (1.00) | NR1H4CYP3A4KCNH2CYP2C9CYP2D6 | |
| SCHEMBL3562525 | 0.88 | NR1H4 (1.00) | NR1H4CYP3A4KCNH2CYP2C9CYP2D6 | |
| SCHEMBL3562530 | 0.88 | NR1H4 (1.00) | NR1H4CYP3A4KCNH2CYP2C9CYP2D6 | |
| SCHEMBL3568324 | 0.88 | NR1H4 (1.00) | NR1H4CYP3A4KCNH2CYP2C9CYP2D6 | |
| SCHEMBL3562698 | 0.88 | NR1H4 (1.00) | NR1H4CYP3A4KCNH2CYP2C9CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7645785-B2 | Benzimidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-01-12 | — | — | US | claimed |
| US-20080021027-A1 | Novel benzimidazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2008-01-24 | — | — | US | claimed |
| US-10071108-B2 | Methods and pharmaceutical compositions for the treatment of hepatitis b virus infection | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2018-09-11 | — | — | US | disclosed |
| US-20180169115-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2018-06-21 | — | — | US | disclosed |
| US-20160220586-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2016-08-04 | — | — | US | disclosed |
| US-7645785-B2 | Benzimidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-01-12 | — | — | US | disclosed |
| US-20080021027-A1 | Novel benzimidazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180169115-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | NR1H4, FXR2, FXR1 | NR1H4 1/4885CYP3A4 170/4885KCNH2 4626/4885 |
| US-20160220586-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | NR1H4, NR1H3, FXR2 | NR1H4 1/4885CYP3A4 125/4885KCNH2 4571/4885 |
| US-20080021027-A1 | Novel benzimidazole derivatives | NR1H4, GPR119, GLP1R | NR1H4 1/4885CYP3A4 291/4885KCNH2 3647/4885 |
| US-10071108-B2 | Methods and pharmaceutical compositions for the treatment of hepatitis b virus infection | NR1H4, FXR2, FXR1 | NR1H4 1/4885CYP3A4 170/4885KCNH2 4626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.